Malaria has been a major global health problem of humans through history and is a leading
cause of death and disease across many tropical and subtropical countries. Over the last …

The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s
heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria …

Background Although the clinical efficacy of antimalarial artemisinin-based combination
therapies in Africa remains high, the recent emergence of partial resistance to artemisinin in …

Abstract Background Partial resistance of Plasmodium falciparum to the artemisinin
component of artemisinin-based combination therapies, the most important malaria drugs …

Abstract Background In the six Southeast Asian countries that make up the Greater Mekong
Subregion, Plasmodium falciparum has developed resistance to derivatives of artemisinin …

Artemisinin resistance (delayed P. falciparum clearance following artemisinin-based
combination therapy), is widespread across Southeast Asia but to date has not been …

Background Partial artemisinin resistance is suspected if delayed parasite clearance (ie,
persistence of parasitaemia on day 3 after treatment initiation) is observed. Validated …

Background The emergence and spread of resistance in Plasmodium falciparum malaria to
artemisinin combination therapies in the Greater Mekong subregion poses a major threat to …

A marked decrease in malaria-related deaths worldwide has been attributed to the
administration of effective antimalarials against Plasmodium falciparum, in particular …

The urea functionality is inherent to numerous bioactive compounds, including a variety of
clinically approved therapies. Urea containing compounds are increasingly used in …